Intercell AG

EANS-News: Intercell and Boehringer Ingelheim Vetmedica GmbH enter into strategic partnership to develop animal vaccines

- » Worldwide agreement for the use of certain Intercell's AIP®-derived antigens to develop and commercialize animal vaccines » Intercell to receive upfront, option and milestone payments as well as royalties on product net sales -------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information Subtitle: - » Worldwide agreement for the use of certain Intercell's AIP®-derived antigens to develop and commercialize animal vaccines » Intercell to receive upfront, option and milestone payments as well as royalties on product net sales Vienna (Austria), May 10, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) today announced that it has entered into a worldwide Option and Exclusive License Agreement under which Boehringer Ingelheim Vetmedica has the right to use certain antigens derived from Intercell´s Antigen Identification Program (AIP®) to develop animal vaccines. Under the agreement, Intercell will receive upfront, option and milestone payments as well as royalties on product net sales. "Having partnered a number of our vaccine candidates derived from our AIP® with leading human vaccine players such as Merck and Novartis, we are very pleased to leverage the value of this successful technology also with a major animal vaccine company like Boehringer Ingelheim Vertmedica. This will allow us to further potentiate the technology and explore its technological and economical power beyond the area of human health", stated Gerd Zettlmeissl, CEO of Intercell. "We are pleased to partner with Intercell and to gain access to attractive vaccine targets generated by AIP®. We are committed to develop innovative vaccines to meet the urgent needs for the benefit of animal health," stated Joachim Hasenmaier, CEO of Boehringer Ingelheim Vetmedica. end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Intercell AG Lucia Malfent Vice President, Global Head Corporate Communications Tel. +43 1 20620-1303 lmalfent@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market

Das könnte Sie auch interessieren: